Program
Anti-HER2 Bispecific Antibody TQB2930
Also written as “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection”, “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)” and “TQB2930 injection+TQB2102 for injection”.
In Sino Biopharmaceutical’s pipeline, HER2双抗
. Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 54 open or running | phase 3since Jun 24, 2025 | May 6, 2022 | Dec 2026phase 2 · NCT06202261 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 6, 2022First study: phase 1 study in Advanced CancersFirst studyNCT05380882 · 60 enrolled · China
- Jan 2, 2024Phase 2 study in Breast NeoplasmsNCT06202261 · 154 planned · China
- Jun 24, 2025Phase 3 study in HER2-positive Advanced Breast CancerNCT07047365 · 416 planned · China
- Mar 25, 2026Phase 2 study in Advanced Solid TumorNCT07512583 · 178 planned · China
- Jun 12, 2026Phase 2 study in Colorectal NeoplasmsNCT07653685 · 71 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Breast NeoplasmsNCT06202261
- Jun 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07653685
- Mar 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07512583
- Jun 2028Primary completion: phase 3 study in HER2-positive Advanced Breast CancerNCT07047365
TargetBeta
“HER2双抗”the company's pipeline, read by Claude · source
“A bispecific antibody directed against two distinct domains of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07653685Colorectal Neoplasms · China | 2 | Recruiting | Jun 2027 | 71 |
| NCT07512583Advanced Solid Tumor · China | 2 | Recruiting | Mar 2028 | 178 |
| NCT07047365HER2-positive Advanced Breast Cancer · China | 3 | Recruiting | Jun 2028 | 416 |
| NCT06202261Breast Neoplasms · China | 2 | Recruiting | Dec 2026 | 154 |
| NCT05380882Advanced Cancers · China | 1 | UNKNOWN | Apr 2023 | 60 |
How it is read
Names in the registry
- “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection”, 1 entry
- “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)”, 1 entry
- “TQB2930 injection+TQB2102 for injection”, 1 entry
- “TQB2930+ chemotherapy”, 1 entry
- “TQB2930 for injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.